Cargando…

Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection

The spread of the Omicron SARS-CoV-2 variant underscores the importance of analyzing the cross-protection from previous non-Omicron infection. We have developed a high-throughput neutralization assay for Omicron SARS-CoV-2 by engineering the Omicron spike gene into an mNeonGreen USA-WA1/2020 SARS-Co...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zou, Jing, Xia, Hongjie, Xie, Xuping, Kurhade, Chaitanya, Machado, Rafael R. G., Weaver, Scott C., Ren, Ping, Shi, Pei-Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828871/ https://www.ncbi.nlm.nih.gov/pubmed/35140233 http://dx.doi.org/10.1038/s41467-022-28544-w

Ejemplares similares

Cross-neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
por: Zou, Jing, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Neutralization of SARS-CoV-2 Omicron sublineages by 4 doses of the original mRNA vaccine
por: Xie, Xuping, et al.
Publicado: (2022)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

Cross-neutralization and viral fitness of SARS-CoV-2 Omicron sublineages
por: Xia, Hongjie, et al.
Publicado: (2023)

Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine
por: Kurhade, Chaitanya, et al.
Publicado: (2022)

Determinants and Mechanisms of the Low Fusogenicity and Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Reverse genetic systems of SARS-CoV-2 for antiviral research
por: Kurhade, Chaitanya, et al.
Publicado: (2023)

Determinants and Mechanisms of the Low Fusogenicity and High Dependence on Endosomal Entry of Omicron Subvariants
por: Qu, Panke, et al.
Publicado: (2023)

Less neutralization evasion of SARS-CoV-2 BA.2.86 than XBB sublineages and CH.1.1
por: Hu, Yanping, et al.
Publicado: (2023)

Reduced neutralization against Delta, Gamma, Mu, and Omicron BA.1 variants of SARS-CoV-2 from previous non-Omicron infection
por: Pidal, Paola, et al.
Publicado: (2022)

Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants
por: Pitts, Jared, et al.
Publicado: (2022)

Antibody escape and cryptic cross-domain stabilization in the SARS-CoV-2 Omicron spike protein
por: Javanmardi, Kamyab, et al.
Publicado: (2022)

Plasma Neutralization of the SARS-CoV-2 Omicron Variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Neutralization and Stability of SARS-CoV-2 Omicron Variant
por: Zeng, Cong, et al.
Publicado: (2021)

A Single-Round Infection Fluorescent SARS-CoV-2 Neutralization Test for COVID-19 Serological Testing at a Biosafety Level-2 Laboratory
por: Zou, Jing, et al.
Publicado: (2022)

Distinct neutralizing kinetics and magnitudes elicited by different SARS-CoV-2 variant spikes
por: Liu, Yang, et al.
Publicado: (2021)

Protection against the Omicron Variant from Previous SARS-CoV-2 Infection
por: Altarawneh, Heba N., et al.
Publicado: (2022)

Plasma neutralization properties of the SARS-CoV-2 Omicron variant
por: Schmidt, Fabian, et al.
Publicado: (2021)

Immune evasion of neutralizing antibodies by SARS-CoV-2 Omicron
por: Wang, Lidong, et al.
Publicado: (2023)

Broadly neutralizing human antibodies against Omicron subvariants of SARS-CoV-2
por: Chiang, Hsiao-Ling, et al.
Publicado: (2023)

Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies
por: Cao, Yunlong, et al.
Publicado: (2021)

Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes
por: Liu, Yang, et al.
Publicado: (2022)

An Integrated Research–Clinical BSL-2 Platform for a Live SARS-CoV-2 Neutralization Assay
por: Zou, Jing, et al.
Publicado: (2023)

SARS-CoV-2 Omicron triggers cross-reactive neutralization and Fc effector functions in previously vaccinated, but not unvaccinated, individuals
por: Richardson, Simone I., et al.
Publicado: (2022)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

Spherical neutralizing aptamer suppresses SARS-CoV-2 Omicron escape
por: Sun, Miao, et al.
Publicado: (2022)

Impact of Reinfection with SARS-CoV-2 Omicron Variants in Previously Infected Hamsters
por: Shiwa-Sudo, Nozomi, et al.
Publicado: (2023)

The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era
por: Boaventura, Viviane S, et al.
Publicado: (2023)

Modeling transmission of SARS-CoV-2 Omicron in China
por: Cai, Jun, et al.
Publicado: (2022)

Neutralizing Potency of Prototype and Omicron RBD mRNA Vaccines Against Omicron Variant
por: Zang, Jinkai, et al.
Publicado: (2022)

A booster dose of Delta × Omicron hybrid mRNA vaccine produced broadly neutralizing antibody against Omicron and other SARS-CoV-2 variants
por: Lee, I-Jung, et al.
Publicado: (2022)

Comparison of COVID-19 pneumonia during the SARS-CoV-2 Omicron wave and the previous non-Omicron wave in a single facility
por: Ito, Noriaki, et al.
Publicado: (2022)

Neutralizing immunity against SARS-CoV-2 Omicron BA.1 by infection and vaccination
por: Duan, Li-Jun, et al.
Publicado: (2022)

Neutralizing antibodies and their cocktails against SARS-CoV-2 Omicron and other circulating variants
por: Yang, Yang, et al.
Publicado: (2022)

Neutralization susceptibility of Omicron lineages
por: Minton, Kirsty
Publicado: (2022)

A live-attenuated SARS-CoV-2 vaccine candidate with accessory protein deletions
por: Liu, Yang, et al.
Publicado: (2022)

Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera
por: Shi, Pei-Yong, et al.
Publicado: (2021)

Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies
por: Wang, Yingdan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ri3tpnmqb70p4cer5099it6c9b